Can coenzyme Q10 improve clinical and molecular parameters in fibromyalgia?
Cordero MD
Published in Antioxidants & Redox Signaling
Methodology
Double-blind, placebo-controlled randomized trial of CoQ10 (300 mg/day) for 40 days in fibromyalgia patients, with clinical questionnaires and molecular assays of oxidative stress and mitochondrial biogenesis.
Key Findings
Coenzyme Q10 supplementation in fibromyalgia patients improved clinical symptom scores (pain, fatigue and tender points) alongside improvements in mitochondrial and oxidative-stress markers in blood mononuclear cells.
Conclusions
These results lead to the hypothesis that CoQ10 have a potential therapeutic effect in FM, and indicate new potential molecular targets for the therapy of this disease.
Limitations
Very small sample (n=20), short duration and single-centre design; molecular endpoints are surrogates of uncertain clinical meaning.
Supplements Studied
These results lead to the hypothesis that CoQ10 have a potential therapeutic effect in FM, and indicate new potential molecular targets for the therapy of this disease.
Outcomes Measured
Coenzyme Q10 supplementation in fibromyalgia patients improved clinical symptom scores (pain, fatigue and tender points) alongside improvements in mitochondrial and oxidative-stress markers in blood mononuclear cells.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.